JP2025510739A5 - - Google Patents
Info
- Publication number
- JP2025510739A5 JP2025510739A5 JP2024556187A JP2024556187A JP2025510739A5 JP 2025510739 A5 JP2025510739 A5 JP 2025510739A5 JP 2024556187 A JP2024556187 A JP 2024556187A JP 2024556187 A JP2024556187 A JP 2024556187A JP 2025510739 A5 JP2025510739 A5 JP 2025510739A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- lpa
- grna
- disease
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263322078P | 2022-03-21 | 2022-03-21 | |
| US63/322,078 | 2022-03-21 | ||
| US202263351542P | 2022-06-13 | 2022-06-13 | |
| US63/351,542 | 2022-06-13 | ||
| US202263385093P | 2022-11-28 | 2022-11-28 | |
| US63/385,093 | 2022-11-28 | ||
| PCT/IB2023/052720 WO2023180904A1 (en) | 2022-03-21 | 2023-03-20 | Methods and compositions for treating lipoprotein-related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510739A JP2025510739A (ja) | 2025-04-15 |
| JP2025510739A5 true JP2025510739A5 (https=) | 2026-03-25 |
Family
ID=85873796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556187A Pending JP2025510739A (ja) | 2022-03-21 | 2023-03-20 | リポタンパク質関連疾患を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20230293646A1 (https=) |
| EP (1) | EP4496891A1 (https=) |
| JP (1) | JP2025510739A (https=) |
| CN (1) | CN119053705A (https=) |
| AU (1) | AU2023240501A1 (https=) |
| TW (1) | TW202403046A (https=) |
| WO (1) | WO2023180904A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117568313B (zh) * | 2024-01-15 | 2024-04-26 | 上海贝斯昂科生物科技有限公司 | 基因编辑组合物及其用途 |
| WO2025166325A1 (en) * | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2026008063A1 (en) * | 2024-07-05 | 2026-01-08 | Geneditbio Limited | Methods and compositions for lpa gene editing and therapy using crispr system |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
| CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| WO2013059475A1 (en) | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| EP3155129B1 (en) | 2014-06-10 | 2019-01-16 | CureVac AG | Method for enhancing rna production |
| EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| WO2017066793A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
| SI3362461T1 (sl) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Analogi kape MRNA z modificirano fosfatno povezavo |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| KR20250078597A (ko) * | 2015-11-06 | 2025-06-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포리포프로테인 (a) 발현 조정 |
| LT3436077T (lt) * | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| WO2019204668A1 (en) * | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
| MX2022012683A (es) * | 2020-04-09 | 2023-01-11 | Verve Therapeutics Inc | Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades. |
-
2023
- 2023-03-20 US US18/186,943 patent/US20230293646A1/en not_active Abandoned
- 2023-03-20 JP JP2024556187A patent/JP2025510739A/ja active Pending
- 2023-03-20 EP EP23715251.7A patent/EP4496891A1/en active Pending
- 2023-03-20 AU AU2023240501A patent/AU2023240501A1/en active Pending
- 2023-03-20 WO PCT/IB2023/052720 patent/WO2023180904A1/en not_active Ceased
- 2023-03-20 TW TW112110263A patent/TW202403046A/zh unknown
- 2023-03-20 CN CN202380037582.8A patent/CN119053705A/zh active Pending
- 2023-03-20 US US18/849,438 patent/US20250228975A1/en active Pending
-
2024
- 2024-09-20 US US18/892,061 patent/US20250144183A1/en active Pending
- 2024-09-20 US US18/892,051 patent/US20250011771A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510739A5 (https=) | ||
| Li et al. | Ketogenic diets and protective mechanisms in epilepsy, metabolic disorders, cancer, neuronal loss, and muscle and nerve degeneration | |
| Kotulska et al. | Recombinant adeno-associated virus serotype 9 gene therapy in spinal muscular atrophy | |
| CN110934873B (zh) | 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用 | |
| Xu et al. | Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats | |
| Tariot et al. | Can lithium or valproate untie tangles in Alzheimer’s disease | |
| CN104955451A (zh) | 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用 | |
| Caminati et al. | Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group | |
| AU2002250942A1 (en) | Compositions of biochemical compounds involved in bioenergy metabolism of cells | |
| PT2650381T (pt) | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida | |
| AU2019384547A1 (en) | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease | |
| AU2015258892A1 (en) | Methods and compositions for treatment of macrophage-related disorders | |
| Halim et al. | Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel | |
| TW202116331A (zh) | 治療或預防脊髓性肌萎縮之方法 | |
| Raghavan et al. | Improving the therapeutic efficacy of gene therapy for duchenne muscular dystrophy (DMD) by evaluating and managing inflammation | |
| JP2022546550A5 (https=) | ||
| JP2025507751A5 (https=) | ||
| Gordon et al. | The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives–webinar version scientific summary | |
| JP2024527525A5 (https=) | ||
| CN118236379A (zh) | Stm2457在制备防治肺动脉高压的药物中的应用 | |
| US20240301408A1 (en) | Microrna 195 compositions and methods for treating cognitive impairment | |
| MX2008010881A (es) | Modulacion de expresiones de genes por el acido docosahexaenoico. | |
| Baird et al. | Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms | |
| US6737271B1 (en) | Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders | |
| Chebli et al. | 15-year retrospective analysis of Glybera (alipogene tiparvovec) gene replacement therapy for lipoprotein lipase deficiency |